文摘
RAL plus unboosted ATV is an option for NRTI- and RTV-sparing dual regimen. Of 102 patients observed, 77.5% had virological response after more than 2 years follow-up. A concerning rate (18.6%) failed with newly selected mutations. Safety and tolerability profile was confirmed, only 4 discontinued for intolerance. RAL plus ATV might be considered in selected adherent patients.